News Releases

Nov 03, 2022
Axcella to Present at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting
Nov 01, 2022
Axcella Reports Third Quarter Financial Results and Provides Business Update
Oct 27, 2022
Axcella Therapeutics to Report Third Quarter 2022 Financial Results on November 1, 2022
Oct 14, 2022
Axcella Therapeutics to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference
Oct 13, 2022
Axcella Therapeutics Announces $34.2 Million Registered Direct Offering of Common Stock Priced At The Market: Appoints Two New Board Members
Sep 29, 2022
Axcella Announces Positive Interim Data from Phase 2b EMMPACT Study of AXA1125 in Nonalcoholic Steatohepatitis (NASH)
Sep 12, 2022
Axcella Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
Aug 12, 2022
Axcella Reports Second Quarter Financial Results and Provides Business Update
Aug 02, 2022
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
May 26, 2022
Axcella Announces Completion of Enrollment of Clinical Trial for Long COVID and Has Prioritized its Clinical Portfolio
Displaying 1 - 10 of 20